Institutional shares held 3.29 Million
4.8K calls
119K puts
Total value of holdings $8.06M
$11K calls
$292K puts
Market Cap $39.2M
15,985,600 Shares Out.
Institutional ownership 20.58%
# of Institutions 34


Latest Institutional Activity in IRIX

Top Purchases

Q1 2024
Amh Equity LTD Shares Held: 456K ($1.12M)
Q1 2024
Citadel Advisors LLC Shares Held: 38.9K ($95.3K)
Q1 2024
Perkins Capital Management Inc Shares Held: 45.3K ($111K)
Q1 2024
Group One Trading, L.P. Shares Held: 5.44K ($13.3K)
Q1 2024
Vanguard Group Inc Shares Held: 561K ($1.37M)

Top Sells

Q1 2024
Susquehanna International Group, LLP Shares Held: 85.4K ($209K)
Q1 2024
Ubs Group Ag Shares Held: 189 ($463)
Q1 2024
Renaissance Technologies LLC Shares Held: 410K ($1M)
Q1 2024
Black Rock Inc. Shares Held: 54.4K ($133K)
Q1 2024
Wolverine Trading, LLC Shares Held: 16.3K ($39.9K)

About IRIX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.


Insider Transactions at IRIX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
316K Shares
From 6 Insiders
Grant, award, or other acquisition 316K shares
Sell / Disposition
22.6K Shares
From 2 Insiders
Payment of exercise price or tax liability 22.6K shares

Track Institutional and Insider Activities on IRIX

Follow IRIDEX CORP and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IRIX shares.

Notify only if

Insider Trading

Get notified when an Iridex Corp insider buys or sells IRIX shares.

Notify only if

News

Receive news related to IRIDEX CORP

Track Activities on IRIX